Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

800.42 -2.75 (-0.34%)
Streaming Delayed Price Updated: 10:15 AM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
79 80 Next >
Magnificent 7 Take Center Stage In Hedge Fund Portfolios: Analysts Warn Of Extreme Concentration
Hedge fund portfolios are intensifying their focus on technology stocks, with holdings in mega-cap tech reaching record levels. 
Via Benzinga
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,... 
Via Benzinga
Topics ETFs
Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now
Investors have favored an exciting billion-dollar opportunity at Eli Lilly. 
Via The Motley Fool
Uncovering Noteworthy Technical Analysis Findings for ELI LILLY & CO (NYSE:LLY).
Promising Signs: ELI LILLY & CO Setting the Stage for a Breakout. 
Via Chartmill
Analyst Expectations for Eli Lilly's Future
Via Benzinga
A Look Into Eli Lilly Inc's Price Over Earnings
Via Benzinga
Eli Lilly Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Better Growth Stock: Novo Nordisk vs. Eli Lilly
These companies have been attracting plenty of attention lately. 
Via The Motley Fool
Eli Lilly Just Got One Step Closer to Dethroning Ozempic. Time to Buy the Stock?
Eli Lilly just received FDA approval for its obesity medication Zepbound, the sister treatment to its blockbuster drug Mounjaro. 
Via The Motley Fool
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Relative Strength Index (RSI) Indicator: Does It Work?
The Relative Strength Index (RSI) is a contrarian technical analysis indicator that uses prices to find "overbought" and "oversold" assets. 
Via InvestorPlace
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
Goldman Sachs' 2024 Equity Outlook: Winning Stocks And Sectors To Watch
Dive into Goldman Sachs' 2024 Equity Outlook, detailing a positive forecast for the S&P 500, sector-specific strategies, and key stock picks for navigating a year of growth and stability. 
Via Benzinga
Topics Stocks
Exposures US Equities
Eli Lilly Unusual Options Activity
Via Benzinga
Pharmaceutical Giant Eli Lilly Plans Expansion In Germany, Eyes Diabetes Drug Production: Report
Eli Lilly And Co (NYSE: LLY) reportedly intends to construct a production plant in western Germany with an estimated investment of €2 billion ($2.17 billion), marking an inaugural substantial... 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
If You Invested $10,000 in Eli Lilly in 2013, This Is How Much You Would Have Today
Is it too late to invest in Eli Lilly's stock? 
Via The Motley Fool
Why Eli Lilly Stock Flopped While the Market Popped Today
The company is apparently gearing up to spend at least $1 billion on a production facility in Europe. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Ozempic Shortage Crisis - Germany Weighs Export Restrictions on Novo Nordisk's Drug
Germany's Federal Institute for Drugs and Medical Devices (BfArM) is reportedly contemplating a potential export prohibition on Novo Nordisk A/S's (NYSE: NVO) popular diabetes medication, Ozempic,  
Via Benzinga
Why It’s Time to Sell These 3 Hot Stocks
Holding onto a stock too long can lead to an evaporation of profits. Better for investors to sell a little too early than a little too late. 
Via InvestorPlace
Eli Lilly Is Planning to Dominate the Weight Loss Market and Make Billions. Here's Why It'll Keep Winning
It's already taking actions to shore up its future position. 
Via The Motley Fool
Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip.
Choosing dividend aristocrats to buy becomes easy when you elect to buy the royalty of income-generating stocks. 
Via InvestorPlace
What Are Pfizer's Prospects In Obesity Pill Market? Analysts Say Optimism, Cautiousness Surround With Data Awaited Next Year
Pfizer Inc (NYSE: PFE) is turning its focus to the weight loss drug market, aiming to capture a $10 billion segment with its experimental obesity  
Via Benzinga
Is There Room for Improvement In Weight Loss Arena? Analysts Evaluate Novo Nordisk Data, Emphasize Opportunities for Eli Lilly
Eli Lilly And Co's (NYSE: LLY) investigational RNA-directed drug lepodisiran lowered lipoprotein(a) levels in a Phase 1 study. Elevated levels of Lp(a) have been associated with a higher risk of heart... 
Via Benzinga
Novo Nordisk, Eli Lilly Skid — But These Weight-Loss Results Are 'Hard To Ignore'
Patients who took Wegovy for five years had a 70% reduced risk of developing diabetes. 
Via Investor's Business Daily
The Magnificent Seven: 7 Stocks That Could Make It the ‘Elite Eight’
Investors curious to identify the next magnificent 7 stock should start here as the clues are fairly straightforward. 
Via InvestorPlace
Better Buy Now: Novo Nordisk vs. Eli Lilly
Both of these companies are reporting positive news for their competing weight-loss drugs, but which is the better stock to buy now? 
Via The Motley Fool
Wegovy Weight Loss Drug Cuts Heart Complication Risk, Says Trial
A clinical trial has revealed that Novo Nordisk's (NYSE: NVO) weight loss drug Wegovy significantly decreases the risk of serious heart complications. 
Via Benzinga
'Market's Had A Very Solid Winning Streak Of Late': Jim Cramer Eyes Key Retailers And CPI Data In Critical Earnings Week Ahead
CNBC market analyst Jim Cramer emphasized the importance of the upcoming week for investors,  
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
79 80 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.